Silexion Therapeutics Corp Stock Price, News & Analysis

Silexion Therapeutics (NASDAQ:SLXN) announced positive preclinical data for its pancreatic cancer drug SIL204. The study demonstrated that subcutaneously administered SIL204 successfully reached major pancreatic cancer metastatic sites and showed anti-tumor activity.

Key findings include successful drug distribution to liver, peritoneum, and lung following a single subcutaneous injection at 5mg/mouse, with statistically significant reductions (p<0.01) in tumor burden observed in the peritoneum, lung, and intestine. The results validate the systemic component of Silexion's dual-route administration strategy.

The company remains on track to initiate Phase 2/3 clinical trials in H1 2026, with regulatory submissions planned for Q4 2025 and Q1 2026.

Silexion Therapeutics (NASDAQ:SLXN) has selected AMS Advanced Medical Services GmbH as its Contract Research Organization (CRO) to support upcoming Phase 2/3 clinical trials for SIL204, their RNA interference therapy targeting KRAS-driven cancers.

The partnership follows impressive preclinical results showing up to 97% inhibition in pancreatic cancer cells, ~90% inhibition in colorectal cancer cells, and significant activity in lung cancer cell lines. SIL204 has demonstrated effectiveness against multiple KRAS mutations including G12D, G12V, G12R, Q61H, and G13D.

Regulatory submissions are planned for Q4 2025 (Israel) and Q1 2026 (EU), with Phase 2/3 trials expected to commence in H1 2026. The trials will evaluate SIL204's dual-route administration approach in locally advanced pancreatic cancer patients.

Silexion Therapeutics (NASDAQ:SLXN), a clinical-stage biotech company focused on RNA interference therapies for KRAS-driven cancers, will present at the 27th Annual H.C. Wainwright Global Investment Conference. The presentation is scheduled for September 10, 2025, at 2:00 PM ET at the Lotte New York Palace Hotel.

The company has uploaded an updated corporate presentation to their website's investor section. Management will be available for one-on-one meetings with investors during the conference, which can be arranged through H.C. Wainwright representatives.

Silexion Therapeutics (NASDAQ: SLXN) reported Q2 2025 financial results and business updates, highlighting significant progress in its SIL204 preclinical program for KRAS-driven cancers. The company demonstrated strong efficacy data across multiple cancer types, including 94% inhibition in pancreatic cancer, 90% in colorectal cancer, and significant inhibition in lung cancer cells with KRAS G12D mutations.

Key developments include a strategic partnership with Catalent for formulation development, plans to initiate Phase 2/3 clinical trials in H1 2026, and maintaining Nasdaq listing following a 1-for-15 reverse split. Financial results show cash position of $3.5 million as of June 30, 2025, with Q2 net loss of $2.5 million, up from $1.5 million in Q2 2024.

Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech company focused on RNAi therapies for KRAS-driven cancers, has announced warrant exercise agreements totaling $1.8 million in gross proceeds. The agreement involves the immediate exercise of 152,106 outstanding warrants at $11.57 per share.

As part of the transaction, the company will issue new unregistered warrants to purchase up to 304,212 ordinary shares at an exercise price of $11.32 per share. These new warrants will have a 24-month term and will become exercisable following shareholder approval of increased authorized shares. H.C. Wainwright & Co. serves as the exclusive placement agent for this offering.

Silexion Therapeutics (NASDAQ: SLXN) has announced breakthrough preclinical data for its RNA interference therapy SIL204, demonstrating exceptional cancer cell growth inhibition rates. The study showed up to 97% inhibition in pancreatic cancer cells and 90% in colorectal cancer cells, including first-time evidence against the KRAS Q61H mutation.

Key findings revealed dose-dependent inhibition of up to 94% in pancreatic cancer cells with KRAS G12D mutations, 97% inhibition in pancreatic cancer cells with KRAS Q61H mutations, and nearly 90% inhibition in colorectal cancer cells with KRAS G12D mutations. The company is preparing for a Phase 2/3 clinical trial in Q2 2026 to investigate SIL204 for KRAS-driven solid tumor cancers.

Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech company developing RNAi therapies for KRAS-driven cancers, has announced a 1-for-15 reverse share split effective after market close on July 28, 2025. Trading on a split-adjusted basis will begin on July 29, 2025.

The reverse split will automatically combine every fifteen ordinary shares into one share, with the par value increasing from $0.0009 to $0.0135 per share. The move aims to maintain Nasdaq listing compliance and follows recent preclinical breakthroughs with SIL-204. Shareholders holding shares in book-entry form or through brokers will have their shares automatically adjusted.

Silexion Therapeutics (NASDAQ: SLXN) has announced positive preclinical results for its SIL204 drug candidate in human lung cancer cell lines. The study demonstrated significant dose-dependent inhibition in lung cancer cells with KRAS G12D mutations, validating the company's lipid-conjugated delivery system.

The company is preparing for a Phase 2/3 clinical trial in Q2 2026 to investigate SIL204 for KRAS-driven solid tumor cancers, utilizing both intratumoral and systemic delivery approaches. Silexion is also conducting additional studies on a previously untested KRAS mutation to potentially establish SIL204 as a pan-KRAS treatment.

The target market is substantial, with KRAS mutations present in 90% of pancreatic cancers, 45% of colorectal cancers, and 30% of lung cancers, representing a combined global treatment market exceeding $30 billion annually.

Silexion Therapeutics (NASDAQ: SLXN) has announced breakthrough preclinical results for its RNAi therapeutic candidate SIL204, showing significant efficacy against pancreatic, colorectal, and lung (NSCLC) cancer cell lines. The drug demonstrated powerful anti-tumor activity in cells with KRAS G12D mutations, achieving an impressive ~90% inhibition rate in GP2D colorectal cancer cells. SIL204's lipid-conjugated delivery system enabled potent activity at nanomolar concentrations across multiple cancer types. The therapy targets KRAS mutations, which occur in approximately 90% of pancreatic cancers, 45% of colorectal cancers, and 35% of non-squamous non-small-cell lung cancers. These indications represent a combined global treatment market exceeding $30 billion annually.